Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy. The inclusion of Dr. Thomas B.

Rezolute, Inc., a company focused on treating hypoglycemia caused by hyperinsulinism, announced that its abstract for a Phase 3 study of its drug Ersodetug will be presented at ENDO 2025 in San ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

In a new study involving whole-genome data, researchers present “CASTER,” a tool that uses arrangements in DNA sequences known as site patterns to infer “species trees,” which are diagrams that depict ...